Edition:
United States

Orion Energy Systems Inc (OESX.OQ)

OESX.OQ on NASDAQ Stock Exchange Capital Market

0.90USD
22 Mar 2019
Change (% chg)

$-0.05 (-5.44%)
Prev Close
$0.96
Open
$0.96
Day's High
$0.98
Day's Low
$0.88
Volume
60,082
Avg. Vol
24,304
52-wk High
$1.24
52-wk Low
$0.54

Latest Key Developments (Source: Significant Developments)

Orion Energy Systems Reports Third Quarter 2019 Results
Thursday, 7 Feb 2019 08:00am EST 

Feb 7 (Reuters) - Orion Energy Systems Inc ::ENERGY-EFFICIENT LED LIGHTING MANUFACTURER ORION REPORTS Q3'19 REVENUE OF $16.3M AND REITERATES FISCAL 2019 GROWTH GOAL OF 5-10%.Q3 REVENUE $16.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $17.5 MILLION.Q3 LOSS PER SHARE $0.02.Q3 EARNINGS PER SHARE ESTIMATE $-0.05 -- REFINITIV IBES DATA.MANAGEMENT IS REITERATING PRIOR DIRECTIONAL GOAL OF 5-10% REVENUE GROWTH IN FISCAL YEAR 2019.EXPECTS STRENGTH FROM LARGE NATIONAL ACCOUNT CUSTOMERS TO CONTINUE IN Q4 AND INTO FISCAL 2020.  Full Article

Orion reports Q2 loss per share $0.13
Thursday, 2 Nov 2017 08:00am EDT 

Nov 2 (Reuters) - Orion Energy Systems Inc :Energy-Efficient led lighting manufacturer orion reports q2'18 revenue of $15.4m and positive cash flow from operations of $1.1m.Sees FY 2019 revenue at least $10 million.Q2 revenue $15.4 million versus I/B/E/S view $17.5 million.Q2 loss per share $0.13.Sees FY 2018 revenue about $13 million.Q2 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Orion Energy Systems Inc - ‍Q2 '18 backlog of $6.5m was flat compared to Q1 '18​.  Full Article

Photo

Bayer, Orion drug shown to delay spread of prostate cancer

FRANKFURT/HELSINKI German drugmaker Bayer and Finland's Orion said on Wednesday a study showed a prostate cancer drug they are jointly developing can delay the spread of the disease to other parts of the body, boosting Orion's shares.